|
Regorafenib granted priority review in the U.S. for second-line treatment of liver cancer
|
07 February 2017 |
|
Regorafenib from Bayer submitted to health authorities seeking approval in second-line treatment of liver cancer
|
09 November 2016 |
|
Bayer shows strong performance
|
26 October 2016 |
|
Bayer and CRISPR Therapeutics joint venture, named Casebia Therapeutics, establishes operations in Cambridge, MA
|
19 August 2016 |
|
Bayer Science & Education Foundation launches new round of funding
|
08 June 2016 |
|
Grants4Apps Accelerator 2016: You imagine, Bayer supports
|
10 May 2016 |
|
Bayer off to a successful start in 2016
|
26 April 2016 |
|
2016 Otto Bayer Award goes to Professor Dr. Dirk Trauner
|
25 April 2016 |
|
Bayer continues to grow its open innovation activities
|
09 February 2016 |
|
Bayer halves the price of its contraceptive implant Jadelle® for women in developing countries
|
08 January 2016 |
|
Bayer and CRISPR Therapeutics AG join forces to discover, develop and commercialize potential cures for serious genetic diseases
|
21 December 2015 |
|
Bayer's new five-year-contraceptive submitted for EU and US marketing authorization
|
20 November 2015 |
|
Bayer aligns organization with Life Science businesses
|
18 September 2015 |
|
New scholarships worth EUR 332,000 awarded by Bayer Foundation to promote international talents
|
16 September 2015 |
|
Bayer significantly improves earnings
|
29 July 2015 |
|
Bayer to divest Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd. for EUR 1,022 million
|
10 June 2015 |
|
Xarelto® approved in China across three indications in the area of venous and arterial thromboembolism
|
07 May 2015 |
|
Strong start to the year for Bayer
|
30 April 2015 |
|
Bayer aspires to significantly expand Life Science businesses
|
11 March 2015 |
|
Bayer forms collaboration with academic and governmental institutions for Rivaroxaban study
|
10 February 2015 |